STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result
The first phone call came some time in late 1996. “Ed, I’d like to introduce…
Category: The Pharmalot View
STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug…
STAT+: Why the drug industry’s opaque warnings on price negotiations fall short
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry…
STAT+: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug pricing
File this under “What was he thinking?” The otherwise staid Milken Institute summit on health…
‘Window dressing’: Eli Lilly’s after-the-fact statement on Indiana’s abortion law sends a disingenuous message
Talk about a delayed reaction. For weeks, a coterie of consumers and businesses tried to…
STAT+: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Whither accelerated approval? Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a…
STAT+: When should drugmakers go all in and cut off essential medicines to Russia?
Just say nyet? As the war in Ukraine intensifies, several of the world’s largest pharmaceutical…
Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most
If a drug maker tested an asthma treatment in children and found it significantly reduced…
‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues
It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in…
Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder
If you think bolstering the pharmaceutical supply chain in the U.S. is a national priority,…
Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels
Never mind the conflicts, there are drugs to approve. In a sorry turn of events,…
‘Deeply problematic’: AmerisourceBergen rewards its CEO despite the ravages of the opioid crisis
You can file this under, “What opioid crisis?” In one of the more startling examples…
‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency
Dear Pascal Soirot, I’d like to talk to you about your priorities. Read the rest……
Pharma drew a line in the sand over Covid-19 vaccine readiness — because someone had to
Talk about a rebuke. President Trump may want a Covid-19 vaccine to ship in time…
FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’
The next 73 days are going to be very difficult for Stephen Hahn. As the…
STAT Plus: Operation Warp Speed doesn’t have the transparency it needs
So much for transparency. In what can only be called a disappointing decision, the Trump…
Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results
When Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, described the results…
We shouldn’t rush to use an unproven drug to treat the coronavirus
As the pandemic deepens, physicians face an agonizing decision — to medicate or not to…
Azar hits a sour note on pricing for a potential coronavirus vaccine
Let them eat cake. This is effectively what Health and Human Services Secretary Alex Azar…